Kasirye, Ronnie
Hume, Heather A.
Bloch, Evan M.
Lubega, Irene
Kyeyune, Dorothy
Shrestha, Ruchee
Ddungu, Henry
Musana, Hellen Wambongo
Dhabangi, Aggrey
Ouma, Joseph
Eroju, Priscilla
de Lange, Telsa
Tartakovsky, Michael
White, Jodie L.
Kakura, Ceasar
Fowler, Mary Glenn
Musoke, Philippa
Nolan, Monica
Grabowski, M. Kate
Moulton, Lawrence H.
Stramer, Susan L.
Whitby, Denise
Zimmerman, Peter A.
Wabwire, Deo
Kajja, Isaac
McCullough, Jeffrey
Goodrich, Raymond
Quinn, Thomas C.
Cortes, Robert
Ness, Paul M.
Tobian, Aaron A. R. http://orcid.org/0000-0002-0517-3766
Funding for this research was provided by:
U.S. Department of Defense (W81XWH1810742)
Article History
Received: 14 January 2022
Accepted: 2 March 2022
First Online: 4 April 2022
Declarations
:
: The MERIT trial protocol was initially approved by the Joint Clinical Research Center Institutional Review Board (JCRCIRB) in Kampala, Uganda, on 8 October 2018 (reference number JC1618). Ethical clearance was also obtained from the UNCST, the Ugandan National Drug Authority, the Johns Hopkins University School of Medicine, and the US Department of Defense Human Research Protection Office (HRPO). Any modifications to the protocol are submitted to all the aforementioned bodies. The current protocol version is 3.0. Administrative clearance was obtained from MNRH, UCI, and KSNRH. Written, informed consent to participate is being obtained from all participants.
: Not applicable
: Except for RG helping to develop the Mirasol PRT system, RC being employed by Terumo BCT, and JM and PN receiving consultancy income from Terumo BCT, the authors declare that they have no competing interests.